Immunovant (IMVT) Cash & Equivalents (2018 - 2026)

Immunovant's Cash & Equivalents history runs 9 years deep, the most recent figure standing at $902.1 million for Q1 2026.

• Quarterly Cash & Equivalents rose 26.35% year-over-year to $902.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $902.1 million (up 26.35% YoY) and the FY2026 annual result came in at $902.1 million, up 26.35% from the prior year.
• Cash & Equivalents was $902.1 million for Q1 2026 at Immunovant, down from $994.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $994.5 million in Q4 2025 and bottomed at $269.9 million in Q3 2023.
• A 5-year average of $541.2 million and a median of $493.8 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents tumbled 45.77% — and 2025, when it soared 165.42%.
• Immunovant's Cash & Equivalents stood at $432.6 million in 2022, then soared by 59.71% to $690.9 million in 2023, then tumbled by 45.77% to $374.7 million in 2024, then jumped by 165.42% to $994.5 million in 2025, then decreased by 9.29% to $902.1 million in 2026.
• Business Quant data shows IMVT's Cash & Equivalents at $902.1 million in Q1 2026, $994.5 million in Q4 2025, and $521.9 million in Q3 2025.